1. Design and Characterization of Erwinia Chrysanthemi l-Asparaginase Variants with Diminished l-Glutaminase Activity*
- Author
-
Ying Su, Hien Anh Nguyen, and Arnon Lavie
- Subjects
0301 basic medicine ,Asparaginase ,Mutant ,Pectobacterium chrysanthemi ,Mutation, Missense ,Biology ,medicine.disease_cause ,Biochemistry ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Bacterial Proteins ,Glutaminase ,Cell Line, Tumor ,medicine ,Humans ,Asparagine ,Molecular Biology ,Mutation ,Dickeya chrysanthemi ,Cell Biology ,Glutamine ,030104 developmental biology ,Cell killing ,chemistry ,Amino Acid Substitution ,030220 oncology & carcinogenesis ,Protein Structure and Folding - Abstract
Current FDA-approved l-asparaginases also possess significant l-glutaminase activity, which correlates with many of the toxic side effects of these drugs. Therefore, l-asparaginases with reduced l-glutaminase activity are predicted to be safer. We exploited our recently described structures of the Erwinia chrysanthemi l-asparaginase (ErA) to inform the design of mutants with diminished ability to hydrolyze l-glutamine. Structural analysis of these variants provides insight into the molecular basis for the increased l-asparagine specificity. A primary role is attributed to the E63Q mutation that acts to hinder the correct positioning of l-glutamine but not l-asparagine. The substitution of Ser-254 with either an asparagine or a glutamine increases the l-asparagine specificity but only when combined with the E63Q mutation. The A31I mutation reduces the substrate Km value; this is a key property to allow the required therapeutic l-asparagine depletion. Significantly, an ultra-low l-glutaminase ErA variant maintained its cell killing ability. By diminishing the l-glutaminase activity of these highly active l-asparaginases, our engineered ErA variants hold promise as l-asparaginases with fewer side effects.
- Published
- 2016